Description: Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California.
Home Page: www.nurixtx.com
NRIX Technical Analysis
1700 Owens Street
San Francisco,
CA
94158
United States
Phone:
415 660 5320
Officers
| Name | Title |
|---|---|
| Dr. Arthur T. Sands M.D., Ph.D. | CEO, Pres & Director |
| Mr. Johannes Van Houte | Chief Financial Officer |
| Ms. Stefani A. Wolff | COO & Exec. VP of Product Devel. |
| Dr. Gwenn M. Hansen Ph.D. | Chief Scientific Officer |
| Dr. Christine Ring | Gen. Counsel & Sec. |
| Dr. John Kuriyan Ph.D. | Founder & Member of Scientific Advisory Board |
| Dr. Michael Rapé Ph.D. | Founder & Member of Scientific Advisory Board |
| Prof. Arthur Weiss M.D., Ph.D. | Founder & Member of Scientific Advisory Board |
| Mr. Howard A. Simon J.D., Esq., SPHR | VP of Operations & Corp. Counsel |
| Rita Kwong | Sr. Accounting Mang. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7012 |
| Price-to-Sales TTM: | 14.3102 |
| IPO Date: | 2020-07-24 |
| Fiscal Year End: | November |
| Full Time Employees: | 242 |